ResMed Defies GLP-1 Fears, Boosts CPAP Demand with Strategic Physician Outreach
RMD sits 28% above its 52-week low of $199.92.
Summary
ResMed is successfully leveraging the weight-loss drug trend, specifically GLP-1s, to boost demand for its CPAP machines, effectively turning a perceived threat into a growth opportunity. This strategy involves targeting primary care physicians who prescribe GLP-1s with educational programs on sleep apnea and CPAP therapy. The company's proactive approach has contributed to robust revenue growth, including an 11% rise in December-quarter revenue, which aligns with the strong Q2 FY26 results reported on January 30, 2026. This strategic adaptation mitigates a significant investor concern regarding the impact of GLP-1 drugs on sleep apnea treatment demand and highlights a new, effective market driver for ResMed's core products.
At the time of this announcement, RMD was trading at $255.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.2B. The 52-week trading range was $199.92 to $293.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.